Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

Video

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Sattva Neelapu, MD, professor of lymphoma and myeloma at The University of Texas MD Anderson Cancer Center, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) are currently the only CAR T-cell products approved for patients with relapsed/refractory large B-cell lymphoma who have failed 2 or more lines of systemic therapy. This indication includes the histologies of diffuse large B-cell lymphoma and high-grade B-cell lymphoma, explains Neelapu.

Currently, these products are used in the third-line setting and beyond, typically after patients with B-cell lymphoma have failed the frontline chemotherapy and the second-line autologous stem cell transplantation. Previously, the outcomes of these patients had been pretty dismal with a median survival of 46 months, according to Neelapu. Updated 2-year data for axi-cel and tisagenlecleucel show durable responses, Neelapu says.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.